Вход на сайт
Просмотр новости

Найдите то, что Вас интересует

Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC
Дата публикации: 23-07-2026 07:07:00

Findings from the BREAKWATER Cohort 3 study

Основное содержимое страницы с новостью.

Subscribe to ESMO newsletter

Login to your ESMO Account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits.

ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH

© Copyright 2026 European Society for Medical Oncology All rights reserved worldwide.

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1EMA Recommends Extension of Therapeutic Indications for Cetuximab011.314-08-2026
2Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC016.811-08-2026
3Ensartinib Improves DFS Outcomes in Patients with ALK-positive, Completely Resected Stage II to IIIB NSCLC01527-07-2026
4Adding Pirtobrutinib to Venetoclax-Rituximab Shows Significant Improvement in PFS Among Patients with Previously Treated CLL014.7606-08-2026
5Benefit of Adjuvant Chemotherapy in Patients with ctDNA-positive Resected Stage II Colon Cancer014.7630-07-2026
6Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence01021-07-2026
7EMA Recommends Extension of Therapeutic Indications for Serplulimab013.8831-07-2026
8Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer01028-07-2026
9Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors0725-06-2026
10Intratumoral Fusobacterium as a prognostic and predictive biomarker in resectable colorectal cancer04.7904-08-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 12.4. Источник: www.esmo.org.